Drug Interactions between E.E.S.-200 and encorafenib
This report displays the potential drug interactions for the following 2 drugs:
- E.E.S.-200 (erythromycin)
- encorafenib
Interactions between your drugs
erythromycin encorafenib
Applies to: E.E.S.-200 (erythromycin) and encorafenib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration of encorafenib with a drug that is both a substrate as well as a moderate inhibitor of CYP450 3A4 may result in increased plasma concentrations of encorafenib and significantly decreased plasma concentrations of the other drug. Encorafenib itself is a substrate and a potent inducer of CYP450 3A4. When a single 50 mg dose of encorafenib (equivalent to 0.1 times the recommended dose) was administered with diltiazem, a moderate CYP450 3A4 inhibitor, encorafenib peak plasma concentration (Cmax) increased by 45% and systemic exposure (AUC) increased by 2-fold. Increased exposure to encorafenib may increase the risk of serious and life-threatening adverse effects such as hemorrhage, uveitis, QT prolongation, hepatotoxicity, dermatologic reactions, and new malignancies. Conversely, administration of a single 2 mg dose of the sensitive CYP450 3A4 substrate midazolam after repeated administration of encorafenib 450 mg once daily and binimetinib 45 mg twice daily resulted in decreased systemic exposure (AUC) and peak plasma concentration (Cmax) of midazolam by approximately 82% and 74%, respectively, compared to midazolam alone. Reduced plasma concentrations may potentially lead to decreased efficacy of the CYP450 3A4 substrate.
MANAGEMENT: Concomitant use of encorafenib with moderate CYP450 3A4 inhibitors that are also sensitive CYP450 3A4 substrates should generally be avoided. If coadministration is required, the manufacturer recommends reducing the encorafenib dose to one-half of the dose used prior to addition of the moderate CYP450 3A4 inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the encorafenib dose that was taken prior to initiating the inhibitor may be resumed. If the concomitant medication also carries a risk of prolonging the QT interval, then obtaining more frequent electrocardiograms (ECGs) to monitor the QT interval may be advisable. Patients should be counseled to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, syncope, palpitations, irregular heartbeat, and/or shortness of breath. The prescribing information for any concomitant medication should be consulted for further guidance and assessment of benefits versus risks of coadministration, as well as any dosage adjustments that may be required during coadministration and/or following the discontinuation of the potent CYP450 3A4 inducer.
Drug and food interactions
encorafenib food
Applies to: encorafenib
You should preferably avoid consumption of grapefruit and grapefruit juice while taking encorafenib. Grapefruit and grapefruit juice can significantly increase the blood levels of encorafenib. This may increase the risk of serious side effects such as bleeding complications, eye and vision problems, liver problems, irregular heart rhythm, and development of new skin cancers. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
erythromycin food
Applies to: E.E.S.-200 (erythromycin)
Food decreases the levels of erythromycin in your body. Take erythromycin on an empty stomach at least 30 minutes before or 2 hours after a meal. This will make it easier for your body to absorb the medication. However, some erythromycin products may be taken without regard to meals. Ask your healthcare provider about your particular prescription if you are uncertain of how to take it. Grapefruits and grapefruit juice may increase erythromycin levels but how this may affect you is not known. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.
erythromycin food
Applies to: E.E.S.-200 (erythromycin)
Information for this minor interaction is available on the professional version.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.